Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-02-10 09:39 am Sale | 2022-12-31 | 13G | AnaptysBio, Inc. ANAB | James E. Flynn | 1,161,826 4.090% | -304,774 (-20.78%) | Filing History |
| 2023-02-10 09:37 am Sale | 2022-12-31 | 13G | Vigil Neuroscience, Inc. VIGL | James E. Flynn | 2,052,010 5.770% | -2,784 (-0.14%) | Filing History |
| 2023-02-10 09:36 am Sale | 2022-12-31 | 13G | Merus N.V. MRUS | James E. Flynn | 2,380,438 5.140% | -141,115 (-5.60%) | Filing History |
| 2023-02-10 09:34 am Unchanged | 2022-12-31 | 13G | Mirum Pharmaceuticals, Inc. MIRM | James E. Flynn | 2,032,335 5.510% | 0 (Unchanged) | Filing History |
| 2023-02-10 09:33 am Purchase | 2022-12-31 | 13G | HilleVax, Inc. HLVX | James E. Flynn | 2,694,101 8.080% | 76,153 (+2.91%) | Filing History |
| 2023-02-10 09:32 am Purchase | 2022-12-31 | 13G | Evolus, Inc. EOLS | James E. Flynn | 3,319,000 5.900% | 288,701 (+9.53%) | Filing History |
| 2023-02-10 09:30 am Purchase | 2022-12-31 | 13G | Enhabit, Inc. EHAB | James E. Flynn | 2,996,000 6.040% | 150,000 (+5.27%) | Filing History |
| 2023-02-10 09:28 am Sale | 2022-12-31 | 13G | Catalyst Pharmaceuticals, Inc. CPRX | James E. Flynn | 5,884,448 5.650% | -176,043 (-2.90%) | Filing History |
| 2023-02-10 09:27 am Purchase | 2022-12-31 | 13G | Brookdale Senior Living Inc. BKD | James E. Flynn | 12,679,651 6.790% | 463,090 (+3.79%) | Filing History |
| 2023-02-01 5:11 pm Purchase | 2023-01-31 | 13G | GeneDx Holdings Corp. WGS | James E. Flynn | 1,733,094 7.260% | 1,161,928 (+203.43%) | Filing History |
| 2023-01-18 7:57 pm Sale | 2023-01-17 | 13D | Oncorus, Inc. ONCR | James E. Flynn | 1,015,154 3.910% | -566,397 (-35.81%) | Filing History |
| 2023-01-13 6:47 pm Sale | 2023-01-11 | 13D | Oncorus, Inc. ONCR | James E. Flynn | 1,581,551 6.090% | -954,635 (-37.64%) | Filing History |
| 2022-12-30 7:15 pm Sale | 2022-12-22 | 13D | Oncorus, Inc. ONCR | James E. Flynn | 2,536,186 9.760% | -470,747 (-15.66%) | Filing History |
| 2022-12-29 5:27 pm Sale | 2022-12-29 | 13G | Delcath Systems, Inc. DCTH | James E. Flynn | 0 0.000% | -500,000 (Position Closed) | Filing History |
| 2022-12-29 5:25 pm Sale | 2022-12-29 | 13G | Vincerx Pharma, Inc. VINC | James E. Flynn | 0 0.000% | -68,966 (Position Closed) | Filing History |
| 2022-12-29 5:24 pm Sale | 2022-12-29 | 13G | Xilio Therapeutics, Inc. XLO | James E. Flynn | 0 0.000% | -2,154,061 (Position Closed) | Filing History |
| 2022-12-23 3:35 pm Purchase | 2022-12-23 | 13G | Terns Pharmaceuticals, Inc. TERN | James E. Flynn | 2,851,287 5.940% | 991,287 (+53.30%) | Filing History |
| 2022-12-21 7:05 pm Purchase | 2022-12-19 | 13D | Oncorus, Inc. ONCR | James E. Flynn | 3,006,933 11.580% | 157,963 (+5.54%) | Filing History |
| 2022-12-01 4:51 pm Sale | 2022-11-22 | 13G | Frazier Lifesciences Acquisition Corporation FLAC | James E. Flynn | 0 0.000% | -2,572,986 (Position Closed) | Filing History |
| 2022-11-23 3:19 pm Unchanged | 2022-11-21 | 13D | Graybug Vision, Inc. GRAY | James E. Flynn | 377,265 24.490% | 0 (Unchanged) | Filing History |